Dapagliflozin
Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
Sold as Ebymect · Edistride · XIGDUO · FORXIGA · FARXIGA
- Drug class
- Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 123
- FDA reports (12 mo)
- 10,281
Overview
Dapagliflozin is an active pharmaceutical ingredient in the Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors group (A10BK). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 71 | June 1, 2026 |
| CA Canada | Health Canada | 42 | May 14, 2026 |
| US United States | FDA | 5 | April 8, 2026 |
| EU European Union | EMA | 5 | May 7, 2026 |
GBUnited Kingdom· MHRA
71 products
Uses
Type 2 diabetes mellitus Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes. 1. Heart failure Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Chronic kidney disease Dapagliflozin is indicated in adults for the treatment of chronic kidney disease.
How to take
CACanada· Health Canada
42 products
Uses
4 Geriatrics 10/2023 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism 01/2025 7 WARNINGS AND PRECAUTIONS, Peri-Operative Considerations 01/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed.
RECENT MAJOR LABEL CHANGES ......................................................................................... 2 TABLE OF CONTENTS ...............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS ...................................................................................................................
1 Pediatrics ............................................................................................................... 2 Geriatrics ...............................................................................................................
USUnited States· FDA
5 products
Uses
1 INDICATIONS AND USAGE FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
• To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1) ] . 73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease.
EUEuropean Union· EMA
5 products
Uses
Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes. 1. Heart failure Dapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure. 3 Chronic kidney disease Dapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.
How to take
Drug interactions
Known interactions involving Dapagliflozin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 298. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL347710282 · revised November 7, 2025
- [2]Health Canada (DPD) · 02435462 · revised March 22, 2025
- [3]FDA DailyMed · 01f90c94-71cb-4a… · revised December 12, 2023 [PDF]
- [4]European Medicines Agency · EMEA/H/C/006006 · revised May 7, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.